CEimpact Podcast

Studies suggest that patients admitted to the hospital with heart failure are inadequately diuresed before discharge. Join host, Geoff Wall, as he reviews the data on acetazolamide for diuresis in heart failure.

The GameChanger
Augmentation of loop diuretics with acetazolamide significantly increases diuresis in persons with heart failure.

Geoff produces music under the name, Prophets of Jupiter. This is the song he mentions at the end of the episode - Time to Dance - Lola K Remix.

The COVID-19 pandemic is still ‘a thing’ and the best source of protection are vaccines. The new bivalent booster vaccine provides opportunities to protect ourselves and our communities. If you, your pharmacist, or technicians need Immunization Training – check out CEimpact’s VIRTUAL Administration Training.  Use discount code THANKYOU to save 10%.

Show Segments
00:00 - Introductions

02:15 - Current Use of IV Diuretics

06:15 - Background on Acetazolamide

08:22 - The ADVOR Study

18:38  - Gamechanger: Study Results

20:32 - Connecting to Practice

25:35 - Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload

Redeem your CPE or CME here

• CPE (Pharmacist) 
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the ADVOR study design
2. Describe the main adverse effects of acetazolamide

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-372-H01-P
Initial release date: 10/17/2022
Expiration date: 10/17/2023
Additional CPE and CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram

The current standard of care is to provide a bolus of 30 mL per kg of isotonic fluid for patients with septic shock. Recent retrospective studies question this practice. Join host, Geoff Wall, as he reviewed a NEJM article on the role of fluids in septic shock.

The GameChanger
Large boluses of fluid during septic shock may have unintended adverse events. Some data show that an approach with restrictive fluids may have no difference in death or adverse outcomes.

The COVID-19 pandemic is still ‘a thing’ and the best source of protection are vaccines. The new bivalent booster vaccine provides opportunities to protect ourselves and our communities. If you, your pharmacist or technicians need Immunization Training – check out CEimpact’s VIRTUAL Administration Training.  Use discount code THANKYOU to save 10%.

Show Segments
00:00 - Introductions
01:38 - Background on Septic Shock and Current Treatment
04:47 - Meyhoff et al Study
15:17 - Gamechanger: Study Findings
22:51 - Connecting to Practice
23:57 - Closing Remarks 

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources

• Restriction of Intravenous Fluid in ICU Patients with Septic Shock

Redeem your CPE or CME here

• CPE (Pharmacist) 
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Critique the Meyhoff et al study evaluating restrictive fluids in septic shock
2. Discuss current approaches to fluid resuscitation in patients with septic shock

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-371-H01-P
Initial release date: 10/10/2022
Expiration date: 10/10/2023
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Get FREE CE for this episode by downloading the CEimpact App (details in the FREE CE section).

The current reality of COVID-19 is reviewed in this episode by Dr. Katelyn Jetelina. Dr. Jetelina is an epidemiologist and author of the wildly popular Newsletter, Your Local Epidemiologist, available via Substack.   

We are losing ~400 Americans a day. During the first week of September, we lost 2,299 people. In August 2022 alone, we lost 15,284 Americans to COVID-19. This means COVID-19 remains the third leading cause of death in our repertoire of threats. And it’s largely preventable[1]. 

Pharmacists continue to support the frontlines of the COVID-19 Pandemic. This episode shares insights on the current reality as well as what you need to know about bivalent boosters, and vaccinating children.

The COVID-19 pandemic is still ‘a thing’ and the best source of protection are vaccines. The new bivalent booster vaccine provides opportunities to protect ourselves and our communities. If you, your pharmacist or technicians need Immunization Training – check out CEimpact’s VIRTUAL Administration Training.  Use discount code THANKYOU to save 10%.

Show Segments

00:00 - Introductions

03:38 - Is COVID-19 Still a Thing?

10:55 - The GameChanger: Bivalent Booster

17:15 - The Different Boosters

19:40 - Applying to Practice: Dosing

22:48 - Pediatric Considerations

28:35 - Closing Thoughts

 References and Resources

1. 400 Americans are dying each day. We cannot accept this reality.  
2. Virtual Immunization Administration Training 
3. Get the CEimpact App 

Host
John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc

Guest
Katelyn Jetelina, MPH, PhD
Publisher, Your Local Epidemiologist

Subscribe to Katelyn's substack - Your Local Epidemiologist to receive a direct line of “translated” public health science to the local, national, and international community.

Redeem your CPE or CME here

• CPE (Pharmacist)
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

 
CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the current state of COVID-19 pandemic the United States
2. Describe the role of a bivalent vaccine for COVID-19

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-370-H-06-P
Initial release date: 10/3/2022
Expiration date: 10/3/2023
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Monkeypox is the newest worldwide pandemic and closely mirrors both COVID-19 and HIV pandemics. A large difference is theoretical vaccines and treatments for monkeypox already exist. In this episode of GameChangers, host Geoff Wall, evaluates tecovirimat, a potential monkeypox treatment and the regulations that made it possible.

The GameChanger
Little to no randomized controlled data exist on tecovirimat’s safety and efficacy in monkeypox. A recent case series helps establish the safety of tecovirimat for monkeypox use.

Show Segments 
00:00 - Introductions
02:40 - Current Issue of Monkeypox
04:02 - Tecovirimat “Animal Rule”
11:19 - The GameChanger: Tecovirimat Case Series
17:20 - Applying to Practice
20:45 - Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and resources:

• Tecovirimat and the Treatment of Monkeypox - Past, Present, and Future Considerations.
• Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection.

Redeem your CPE or CME credit

• CPE (Pharmacist)
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership 

Continuing Education Information:
Learning Objectives:
1. Describe the development and use of tecovirimat under the “Animal Rule”
2. Discuss the latest report of tecovirimat use in US patients with monkeypox

All relevant financial relationships have been mitigated. 

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-354-H01-P
Initial release date: 09/26/22
Expiration date: 09/26/2023
Additional CPE & CME details can be found here 

Follow CEimpact on Social Media:
LinkedIn
Instagram

Pharmacogenomic testing has been widely available for over a decade to help guide pharmacotherapy including antidepressant selection when treating major depressive disorder. Yet, the data hasn’t substantiated improved safety or efficacy. Host Geoff Wall is joined by Sarah Grady, PharmD to evaluate the PRIME study looking at the role of pharmacogenomic testing in depression.

The GameChanger

Pharmacogenomic testing may help decrease adverse effects at 12 weeks, but not 24 weeks. However, the study did identify a potential confounder with L-methylfolate deficiency.


Show Segments
00:00 – Introductions
02:15 – Background on Pharmacogenomic Testing
05:15 – PRIME Care Study
18:10 – Connecting to Practice
20:55 – Gamechanger
22:12 – L-methylfolate Deficiency Treatment
26:25 – Closing Remarks


Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
Sarah Grady, PharmD
Professor of Pharmacy Practice, Drake University

References and resources:

Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.

Redeem your CPE or CME credit

• CPE (Pharmacist) 
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership  

Continuing Education Information:
Learning Objectives:
1. Describe the outcomes and limitations of the PRIME care study
2. Discuss the role of L-methylfolate in the treatment of depression

All relevant financial relationships have been mitigated. 

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-305-H01-P
Initial release date: 09/05/22
Expiration date: 09/05/2023
Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram

Studies have connected racial and cultural bias in students and how they approach patient cases in their respective PharmD curriculum. How can preceptors identify and address potential bias in pharmacy learners to help ensure healthcare equity?
 
Host
Kathy Schott, PhD
CEimpact
 
Guest
LaQuoia Johnson, PharmD, BCPS, DPLA
Pharmacy Consultant
Growing Through It

More about Dr. LaQuoia Johnson 

Dr. LaQuoia Johnson is the author of How Rxacism Manifests: Inside the Small World of Pharmacy, a speaker, educator and champion for Diversity, Equity and Inclusion. Her personal mission is to create opportunities for transformational change in leadership from the lens of Grace. 

She is a graduate of the UNC Eshelman School of Pharmacy, Board Certified in Pharmacotherapy, and is residency trained in acute-care and pharmacy administration. Dr. Johnson spent the last decade providing patient-centered care and supporting others who do. Today, she leverages her knowledge and skills to educate the next generation of pharmacy technicians as an adjunct professor for Pharmacy Technology programs at two community colleges in North Carolina. Additionally, Dr. Johnson serves the State of North Carolina in partnership with the CDC foundation as a pharmacist consultant, and is the CEO of Growing Through It, LLC offering personal and leadership coaching and EDI-centered workshops for youth groups, corporate conferences, churches, and community-based organizations. 

Dr. Johnson resigned from her position in Pharmacy Leadership

Get CE
Click here to access the course

CE Information

At the end of this course, preceptors will be able to:

1.     Discuss the possible impact implicit and explicit bias may have on students' ability to support health equity

2.     Describe strategies preceptors can use help students increase their awareness of their own personal bias

UAN: 0107-0000-25-288-H99-P
Release Date: 9/1/25
Expiration Date: 9/1/28

The speakers have no relevant financial relationships with ineligible companies to disclose.

This program has been:

• Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.
• Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors. 

Want to connect with Dr. LaQuoia Johnson? Check out her website:

https://drlaquoiajohnson.com/

Want more information on this topic? If you are looking for some more specific guidance relative to implicit bias, health care disparities, and cultural competence, check out these courses:

• New Perspectives: Exploring Social Identity Mapping and Implicit Bias Interventions
• Leading with G.R.A.C.E.: Leveraging Diversity, Inclusion and Equity in your Pharmacy Practice

Follow CEimpact on Social Media:
LinkedIn
Instagram

The GINA guidelines were updated in 2021, yet providers may not have rolled out the recent changes in practice. JAMA Clinical Guidelines Synopsis highlighted the major recommendations, including SMART therapy (single maintenance and reliever therapy) with an “A” recommendation. Join host Geoff Wall as he talks about implementing new recommendations into practice with community pharmacist and patient, Jake Galdo.

The GameChanger

Single Maintenance and Reliever Therapy (SMART) is the new standard in asthma management. Inhaled Corticosteroid (ICS) plus formoterol is the medication of choice for maintenance and reliever care in asthma.

Show Segments
00:00 – Introductions
3:30 – Background on Asthma
05:06 – GINA Guidelines on Asthma
12:40 – Gamechanger: SMART Therapy
17:08 - Connecting to Practice
29:20 – Closing Remarks


Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc

References and resources:

• Therapy for Mild to Moderate Asthma. JAMA. 
• Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes

Redeem your CPE or CME credit

• CPE (Pharmacist)
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership  

Continuing Education Information:
Learning Objectives:
1. Discuss the primary and secondary track of asthma treatment according to the GINA guidelines
2. Discuss with patients why the SMART approach to using inhalers to relieve immediate symptoms is preferred.

All relevant financial relationships have been mitigated. 

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-350-H01-P
Initial release date: 09/12/22
Expiration date: 09/12/2023
Additional CPE & CME details can be found here 

Follow CEimpact on Social Media:
LinkedIn
Instagram

High-Intensity Statins have been the treatment of choice for ASCVD. However, the recent non-inferiority RACING study evaluates the role of combination moderate-dose statin plus ezetimibe to high-dose statin in ASCVD. Host Geoff Wall breaks down another potential GameChanger in Pharmacotherapy.

The GameChanger
Combination moderate-dose statins plus ezetimibe may be non-inferior to high-dose statins – and have the benefit of better tolerability.


Show Segments 
00:00 – Introductions 
01:55 – Long-Term Efficacy and Safety of Moderate Intensity Statins with Ezetimibe 
02:55 – Statins and Ezetimibe in ASCVD  
13:52 – The GameChanger 
20:50 – Connecting to Practice  
22:01 – Closing Remarks 

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and resources:

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Redeem your CPE or CME credit

• CPE (Pharmacist) 
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership 

Continuing Education Information:
Learning Objectives:
1. Discuss the RACING study results comparing moderate-dose statin plus ezetimibe to high-dose statins
2. Describe the known ‘nocebo’ effect of muscle-related statin adverse effects.
 

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-310-H01-P
Initial release date: 09/05/22
Expiration date: 09/05/2023
Additional CPE & CME details can be found here 

Follow CEimpact on Social Media:
LinkedIn
Instagram

Vaccine distrust and misinformation is at an all-time high. One claim is that vaccines are responsible for dementias, like Alzheimer’s Disease. A recent database study may show the exact opposite. Join host, Geoff Wall, with guest, Jake Galdo, to discuss the role of vaccines and other therapies in the prevention of Alzheimer’s Disease.

The GameChanger
A recent large propensity matched retrospective database study found that the risk of developing Alzheimer’s Disease was LOWER in persons who received regular influenza vaccines compared to unvaccinated individuals.

 
Show Segments 
00:00 – Introductions 
01:54 – Alzheimer's Disease 
06:00 – Vaccines and Decreasing Risk of Dementia 
08:32 – Association Between Influenza Vaccine and Risk of Alzheimer’s Disease 
16:11 – The GameChanger 
18:35 – Connecting to Practice  
22:45 – Mitigating Risk 
26:03 – Amyloid Plaque  
28:15 – Vaccination Season 
29:54 – Closing Remarks 

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
Jake Galdo, PharmD, MBA, BCPS, BCGP
CEO, Seguridad, Inc
Pharmacist, Ross Bridge Pharmacy
Director, CEimpact


References and resources:

• Risk of Alzheimer’s Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching. 
• Faked Beta-Amyloid Data. What Does It Mean? 

Redeem your CPE or CME credit

• CPE (Pharmacist)
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership  

Continuing Education Information:
Learning Objectives:
1. Discuss the recent study in the Journal of Alzheimer’s Disease concerning dementia risk and influenza vaccines
2. List potential physiologic pathways for the lowered incidence of Alzheimer’s Disease in persons vaccinated.


0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-309-H01-P
Initial release date: 08/29/2022
Expiration date: 08/29/2023
Additional CPE & CME details can be found here 

Follow CEimpact on Social Media:
LinkedIn
Instagram

Insomnia is a common medical condition treated with a variety of pharmacologic (Rx or OTC) and non-pharmacologic options. Yet, little data exist on long-term efficacy and safety on these treatment options. Join host Geoff Wall as he discusses a recent meta-analysis comparing treatments for insomnia.

The GameChanger
All treatments for insomnia, including melatonergic agonists, have poor tolerability. Eszopiclone may be the best tolerated and effective “Z” medication for treatment of insomnia.

Show Segments 
00:00 - Introductions 
01:24 - Insomnia 
04:20 - Insomnia Treatment Options 
19:25 - The GameChanger 
21:36 - Connecting to Practice 
24:06 - Closing Remarks 

 Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

 References and resources:
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.

Redeem your CPE or CME credit

• CPE (Pharmacist) 
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership  

 
Continuing Education Information:
Learning Objectives:
1. Discuss the results of a recent network meta-analysis on treatments of insomnia
2. Compare different pharmacotherapy options for the treatment of insomnia based on a recent meta-analysis


0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-304-H01-P
Initial release date: 08/22/22
Expiration date: 08/22/2023
Additional CPE & CME details can be found here 

Follow CEimpact on Social Media:
LinkedIn
Instagram